Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFYR: Phase 1 Study of AVX70120 and AVX70481 Vaccines in Healthy Adults
NCT06998004Phase 1Completed
- Sponsor
- AstriVax Therapeutics
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Oncolytic Viruses, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AVX70120 and AVX70481 in yellow fever and rabies (7 arms), sponsored by AstriVax Therapeutics. Primary endpoints: Occurrence of solicited adverse events at 14 days, Occurrence of unsolicited adverse events at 1 month and 3 more. Started Jun 2024; status: completed.
02
Drugs
AVX70120AVX70481
03
Conditions
yellow feverrabies
Beyond the preview
Go deeper on NCT06998004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998004.